Alkermes earnings were $348.4M for the trailing 12 months ending Jun 30, 2025, with 23.7% growth year over year. The latest ALKS earnings report on Jun 30, 2025 announced Q2 2025 earnings of $87.1M, up 287.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ALKS reported annual earnings of $367.1M, with 3.2% growth.
ALKS past earnings growth
How has ALKS's earnings growth performed historically?
On ALKS's earnings call on Invalid Date, Alkermes (NASDAQ: ALKS) reported Q2 2025 earnings per share (EPS) of $0.53, up 1.85% year over year. Total ALKS earnings for the quarter were $87.10 million. In the same quarter last year, Alkermes's earnings per share (EPS) was $0.54.
As of the last Alkermes earnings report, Alkermes is currently profitable. Alkermes's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $348.45 million, a 20.69% increase year over year.
What was ALKS's earnings growth in the past year?
As of Alkermes's earnings date in Invalid Date, Alkermes's earnings has grown 23.7% year over year. This is 5 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 18.7%. ALKS earnings in the past year totalled $348.45 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.